Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?
{{output}}
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several advanced malignancies leading to durable remission in a subset of patients. Their rapidly expanding use has led to an increased frequency of immune-related adverse events (irAEs).... ...
